Marks 1983

Methods	ALLOCATION CONCEALMENT: unclear BLINDING: at least one measure was assessed by an independent assessor blind to treatment allocation
Participants	DIAGNOSIS: approximately DSM‐III agoraphobia (96% had spontaneous panic attacks) AGE: mean=34 years SEX: 84% women HISTORY: mean duration of illness=8 years PSYCHIATRIC COMORBIDITY: Moderate to severe depression was excluded. MEDICAL COMORBIDITY: ‐
Interventions	ACUTE PHASE: 14 weeks 1. imipramine (mean=124‐158 mg/d) + behavior therapy (six bi‐weekly 1‐hour sessions; self‐exposure + therapist‐guided exposure or + relaxation) 2. placebo + behavior therapy ACUTE PHASE CO‐INTERVENTION: not specified MAINTENANCE: 14 weeks MODE OF DISCONTINUATION: tapered off over 2 weeks (from week 26 to 28) FOLLOW‐UP: at 6 months and at 18 months after treatment discontinuation. 63% and 56% were successfully followed up, respectively. INTERVENTIONS AFTER TRIAL DISCONTINUATION: 47% received some treatment (antidepressant, benzodiazepine, therapist‐aided exposure)
Outcomes	RESPONSE: >= 2 points reduction in total phobic targets REMISSION: >= 4 points reduction in total phobic targets GLOBAL: ‐ PANIC ATTACK: spontaneous panics AGORAPHOBIA: FQ‐Ag, 4 phobic targets, FQ‐Global GENERAL ANXIETY: Non‐phobic anxiety, FQ‐Anxiety‐Depression, DEPRESSION: HAM‐D FUNCTIONING: ‐
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear